Eli Lilly's new Zepbound single-use vials are priced significantly lower than existing pens, addressing both soaring demand and accessibility issues for weight-loss medications.
Patrik Jonsson stated, "These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option."
The company emphasized that vials will be sold exclusively through its telehealth platform LillyDirect, ensuring trust in the authenticity of the medication and tackling counterfeit concerns.
Eli Lilly highlighted that their pricing strategy is designed to alleviate financial barriers for patients without insurance coverage for weight-loss medications, calling for more innovative healthcare solutions.
[
Collection
]
[
|
...
]